Gram-positive Bacterial Infections Market Size (2024 - 2029)

Gram Positive Bacterial Infections Market Analysis

The gram-positive bacterial infections market is expected to register a CAGR of 8.0% over the forecast period.

The outbreak of COVID-19 had impacted the global healthcare system and significantly impacted the gram-positive bacterial infections market. The increase in COVID-19 cases led to an increase in lung complications such as pneumonia and that surged the demand for drugs against gram-positive bacteria. For instance, an article published by John Hopkins Medicine, in February 2022, reported that pneumonia, caused by COVID-19 filled the lungs with fluid, leading to breathing difficulties. The article also reported an increase in pneumonia cases during the pandemic. Thus, COVID-19 led to an increasing demand for drugs against gram-positive bacteria. However, it was anticipated that with a decrease in COVID-19 cases, the demand for these drugs may get reduced as compared to the initial pandemic times. Still, due to the presence of other gram-positive bacterial infections, the demand for drugs against gram-positive bacteria will keep on increasing. The market is expected to witness significant growth over the forecast period.

The factors that are driving this market are the rising prevalence of gram-positive bacterial infections and an increasing number of drug approvals. For instance, an article published by Merck Manual in September 2022, reported that gram-positive bacteria cause severe infections and in some cases, they may be fatal. The article also said that anthrax is a potentially fatal infection caused by gram-positive bacteria. Thus, the high burden of gram-positive bacterial infections is increasing the demand for drugs to treat them.

Similarly, in May 2022, UNICEF reported that globally, there are over 1,400 cases of pneumonia per 100,000 children, or 1 case per 71 children every year, with the greatest incidence occurring in South Asia (2,500 cases per 100,000 children) and West and Central Africa (1,620 cases per 100,000 children). Thus, such a high incidence of pneumonia (gram-positive bacteria infections) is increasing the demand for drugs against them, thereby driving the growth of the studied market.

Furthermore, to overcome this rising infection caused by gram-positive bacteria, many government authorities like the US FDA and Health Canada, etc are taking initiative and approving many antibiotics to treat this bacterial infection. For instance, in 2021, the US FDA approved 50 new molecules to treat rising bacterial infections. These new molecules were approved by the government to overcome and prevent the spread of rising gram-positive bacterial infections. Thus, the introduction of new molecules that may treat a wide range of gram-positive bacterial infections is expected to drive the growth of the studied market.

Therefore, due to the rising prevalence of gram-positive bacterial infections and increasing number of drug approvals, the market is expected to witness significant growth over the forecast period. However, due to antibiotic resistance, the growth of the studied market may get slow which may affect its growth over the forecast period.

Gram Positive Bacterial Infections Industry Segmentation

As per the scope of the report, gram-positive bacteria are among the most common human pathogens associated with clinical infections, which range from mild skin infections to sepsis. Gram-positive bacterial infections include virulence, pathogenesis, immune response, inflammatory response, and drug resistance. several classic gram-positive species cause disease in humans. The most common organisms include Streptococcus, Staphylococcus, Enterococcus, Bacillus, etc. The Gram-Positive Bacterial Infections Market is Segmented by Drug Type (Beta-Lactam Antimicrobials, Fluoroquinolones, Penicillin, Cephalosporins, RNA Immunoprecipitation (RIP), Vaccine, and Other Drugs), Disease (Pneumonia, Sepsis, Pharyngitis, Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections, Endocarditis, Meningitis, and Other Diseases), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (in USD million) for the above segments.